Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.000.81%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 725.40K | 2.30M | 3.72M | 5.11M | 4.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 725.40K | 2.30M | 3.72M | 5.11M | 4.02M |
| Cost of Revenue | 264.80K | 264.80K | 264.80K | 264.80K | 158.10K |
| Gross Profit | 460.60K | 460.60K | 460.60K | 460.60K | -522.40K |
| SG&A Expenses | 5.70M | 5.91M | 5.45M | 5.50M | 6.93M |
| Depreciation & Amortization | 656.10K | 656.10K | 656.10K | 656.10K | 802.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.72M | 6.93M | 6.48M | 6.52M | 8.72M |
| Operating Income | -6.00M | -6.20M | -5.75M | -5.80M | -9.09M |
| Income Before Tax | -13.44M | -13.43M | -11.01M | -9.43M | 165.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.44 | -13.43 | -11.01 | -9.43 | 0.17 |
| Earnings from Discontinued Operations | 6.41M | 5.11M | -3.41M | -4.89M | -4.89M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.02M | -8.32M | -14.42M | -14.32M | -4.73M |
| EBIT | -6.00M | -6.20M | -5.75M | -5.80M | -9.09M |
| EBITDA | -3.22M | -3.39M | -2.93M | -2.97M | -6.11M |
| EPS Basic | -37.38 | -50.69 | -58.66 | -91.47 | -105.16 |
| Normalized Basic EPS | -10.46 | -11.91 | -11.04 | -9.14 | 2.70 |
| EPS Diluted | -37.38 | -50.69 | -58.66 | -91.47 | -105.16 |
| Normalized Diluted EPS | -10.46 | -11.91 | -11.04 | -9.14 | 2.70 |
| Average Basic Shares Outstanding | 69.77M | 27.88M | 2.25M | 1.28M | 974.10K |
| Average Diluted Shares Outstanding | 69.77M | 27.88M | 2.25M | 1.28M | 974.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |